Related Experiment Video

Updated: Dec 7, 2025

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.8K

Targeting respiratory diseases using miRNA inhibitor based nanotherapeutics: Current status and future perspectives

Meenu Mehta1, Saurabh Satija2, Keshav R Paudel3

  • 1Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW, Australia; Centre for Inflammation, Centenary Institute, Sydney, NSW, Australia.

Nanomedicine : Nanotechnology, Biology, and Medicine
|September 27, 2020
PubMed

Insights

MicroRNAs (miRNAs) and their antagonists (antagomiRs) show therapeutic potential for chronic respiratory diseases. Effective lung delivery of these molecules remains a key challenge, driving innovation in nanoparticle-based delivery systems.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • MicroRNAs (miRNAs) are crucial regulators of gene expression in animals and plants.
  • AntagomiRs are synthetic molecules designed to inhibit miRNA activity by blocking target messenger RNA (mRNA) suppression.
  • Modulating miRNA pathways offers significant therapeutic potential for chronic respiratory disorders.

Purpose of the Study:

  • To review the current understanding of miRNA biology and the role of antagomiRs in chronic respiratory diseases.
  • To discuss recent advances in the therapeutic application of antagomiRs, including their use as disease biomarkers.
  • To explore novel delivery systems for antagomiRs in respiratory disease treatment.

Main Methods:

  • Literature review of miRNA biology and antagomiR therapeutics.
  • Analysis of nanoparticle-based delivery systems for miRNA and antagomiRs.
  • Discussion of challenges and future directions in antagomiR delivery for respiratory diseases.

Main Results:

  • Nanoparticle-based systems (polymer, lipid, inorganic) show promise for intracellular delivery of miRNAs/antagomiRs.
  • AntagomiRs have potential as therapeutic agents and biomarkers in chronic respiratory conditions.
  • Delivery to the lungs remains a significant hurdle for clinical application of miRNA-based therapies.

Conclusions:

  • Advancements in delivery systems are critical for realizing the therapeutic potential of antagomiRs in respiratory diseases.
  • Further research into antagomiR biology and targeted delivery is needed.
  • AntagomiRs represent a promising avenue for treating chronic respiratory disorders.
Keywords:
AntagomiRChronic respiratory disordersLung cancerNanotechnologymicroRNA

More Related Videos

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as A Novel Detection and Quantification Method

Published on: October 7, 2025

215
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

660

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
747
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.5K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.5K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K